Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nexavar “Very Competitive” With Pfizer’s Sutent, Bayer Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Bayer’s kidney cancer drug brought in $25.2 mil. (€20 mil.) in the first quarter following its approval late last year.

You may also be interested in...



Bayer/Onyx Nexavar Hits Sales Plateau After Rapid Initial Uptake

Aggressive clinical trial plan aims to add new indications, build Nexavar oncology franchise on kidney cancer success.

Bayer/Onyx Nexavar Hits Sales Plateau After Rapid Initial Uptake

Aggressive clinical trial plan aims to add new indications, build Nexavar oncology franchise on kidney cancer success.

Wyeth CCI-779 Survival Benefit Over Interferon In Kidney Cancer May Warrant First-Line Use

CCI-779 (temsirolimus) monotherapy is associated with a 49% improvement in median overall survival compared to interferon in advanced renal cell carcinoma patients.

Related Content

Topics

UsernamePublicRestriction

Register

PS064190

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel